Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Treatment with donanemab (Kisunla) in patients with a baseline CDR-SB score of 2 who had low to medium tau would extend independence in IADLs by 13 months (95% CI 6-24 months). Alzheimer's ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.